Protagonist Therapeutics (PTGX) Non-Current Assets (2015 - 2026)
Protagonist Therapeutics (PTGX) posted Non-Current Assets of $84.0 million for Q1 2026, up 618.66% sequentially from $11.7 million in Q4 2025, and down 38.36% YoY from $136.3 million in Q1 2025.
Protagonist Therapeutics (PTGX) Non-Current Assets (2015 - 2026) Analysis & Trends
Protagonist Therapeutics has reported Non-Current Assets for 12 years, with the latest figure at $84.0 million in Q1 2026.
- Quarterly Non-Current Assets fell 38.36% year-over-year to $84.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $451.0 million (up 46.06% YoY) and the FY2025 annual result came in at $11.7 million, down 7.28% from the prior year.
- Non-Current Assets improved to $84.0 million in Q1 2026 per PTGX's latest filing, from $11.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $136.3 million in Q1 2025 and troughed at $1.7 million in Q1 2024.
- A 5-year average of $40.3 million and a median of $6.8 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Non-Current Assets tumbled 87.78% in 2022, then jumped 7809.0% in 2025.
- Over 5 years, Non-Current Assets stood at $4.6 million in 2022, then sank by 53.55% to $2.1 million in 2023, then soared by 486.64% to $12.6 million in 2024, then slipped by 7.28% to $11.7 million in 2025, then jumped by 618.66% to $84.0 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $84.0 million, $11.7 million, and $115.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Protagonist Therapeutics | 10.03 Bn | 10.03 Bn | - | 78.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 78.40 Mn |
| Mar 31, 2026 | 84.00 Mn |
| Dec 31, 2025 | 11.69 Mn |
| Sep 30, 2025 | 115.26 Mn |
| Jun 30, 2025 | 115.48 Mn |
| Mar 31, 2025 | 136.27 Mn |
| Dec 31, 2024 | 12.61 Mn |
| Sep 30, 2024 | 127.09 Mn |
| Jun 30, 2024 | 43.70 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 3.53 Mn |
| Mar 31, 2023 | 4.12 Mn |
| Dec 31, 2022 | 4.63 Mn |
| Sep 30, 2022 | 5.56 Mn |
| Jun 30, 2022 | 6.21 Mn |
| Mar 31, 2022 | 6.77 Mn |
| Dec 31, 2021 | 6.96 Mn |
| Sep 30, 2021 | 45.49 Mn |